Pages that link to "Q37915709"

The following pages link to Emerging biological drugs: A new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events (Q37915709):

Displaying 33 items.

• Molecules Great and Small: The Complement System (Q33419651) (← links)
• Risk of epilepsy in patients with systemic lupus erythematosus - a retrospective cohort study (Q34155285) (← links)
• Late-onset systemic lupus erythematosus-associated primary biliary cirrhosis (Q36608499) (← links)
• Healthcare utilization and costs of systemic lupus erythematosus in Medicaid (Q36665317) (← links)
• Vaccine-preventable infections in Systemic Lupus Erythematosus (Q37135056) (← links)
• Long-term treatment of rheumatoid arthritis with adalimumab (Q37358278) (← links)
• Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice. (Q37689638) (← links)
• Autoimmunity in 2011. (Q38021696) (← links)
• Selective TNF-α inhibitor-induced injection site reactions (Q38075021) (← links)
• Is there a cure for systemic lupus erythematosus? (Q38095888) (← links)
• Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors. (Q38107072) (← links)
• Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety (Q38175430) (← links)
• Efficacy and safety of etanercept in chronic immune-mediated disease (Q38198080) (← links)
• Potential use of TNF-α inhibitors in systemic sclerosis (Q38206817) (← links)
• Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy (Q38258624) (← links)
• Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept? (Q38266322) (← links)
• Infection risk associated with anti-TNF-α agents: a review (Q38335718) (← links)
• Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. (Q38578832) (← links)
• Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? (Q38631012) (← links)
• Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals. (Q38718092) (← links)
• Biological drugs in Guillain-Barré Syndrome: an update. (Q38783298) (← links)
• Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis (Q40081220) (← links)
• Advances in our understanding of immunization and vaccines for patients with systemic lupus erythematosus (Q40106216) (← links)
• Biologicals (Q41889270) (← links)
• Biological therapy in systemic lupus erythematosus (Q42141973) (← links)
• The Future of Autoimmunity (Q43786536) (← links)
• Is integrative medicine the next new frontier in medicine? (Q44067289) (← links)
• Complement and autoimmunity (Q45169996) (← links)
• Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis (Q45354677) (← links)
• Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis (Q48020447) (← links)
• Analysis of human biologics with a mouse skin transplant model in humanized mice (Q50942355) (← links)
• Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-α therapy. (Q51060097) (← links)
• Complement and Complement Targeting Therapies in Glomerular Diseases (Q92327732) (← links)